|1.||Peters, Godefridus J: 8 articles (06/2014 - 03/2005)|
|2.||Fukushima, Masakazu: 7 articles (06/2014 - 03/2005)|
|3.||Nakagawa, Fumio: 4 articles (09/2015 - 02/2004)|
|4.||Temmink, Olaf H: 4 articles (05/2010 - 03/2005)|
|5.||Bijnsdorp, Irene V: 3 articles (06/2014 - 02/2010)|
|6.||Hill, James M: 3 articles (02/2009 - 06/2003)|
|7.||Takechi, Teiji: 2 articles (09/2015 - 05/2015)|
|8.||Yoshisue, Kunihiro: 2 articles (09/2015 - 08/2015)|
|9.||Chiba, Masato: 2 articles (09/2015 - 08/2015)|
|10.||Kuwata, Keizo: 2 articles (08/2015 - 10/2008)|
04/01/2011 - "A diagnosis of herpetic epithelial keratitis was made based on the clinical findings, and he was subsequently treated with 1 drop of trifluridine 9 times per day in the affected eye. "
04/01/2004 - "[Trifluridine therapy in herpetic in keratitis]."
06/01/2003 - "The effect of 1% VVACV on epithelial keratitis induced by inoculation of HSV-1 strain McKrae (25 microL of 10(5) plaque-forming units [PFU]) in the scarified rabbit cornea and stromal keratitis induced by intrastromal injection of HSV-1 strain RE (10 microL of 10(5) PFU) was compared with that of 1% trifluorothymidine (TFT) and balanced salt solution as the vehicle control. "
10/01/1984 - "Six eyes of four patients with Thygeson's superficial punctate keratitis were treated with trifluridine 1% drops. "
10/01/1984 - "Effect of topical trifluridine on Thygeson's superficial punctate keratitis."
04/01/2004 - "The results of the study indicate trifluridine as an efficient antiviral drug which may be successfully used in the treatment of herpetic keratitis (superficial and stromal)."
01/01/1984 - "[Trifluorothymidine therapy of corticoid-treated herpetic keratitis: experimental study in the rabbit]."
01/01/1983 - "Prolonged topical trifluridine treatment of herpes simplex keratitis in three elderly patients produced slightly raised dysplastic corneal epithelial lesions. "
05/01/1982 - "Thus, trifluridine is an effective alternative to the drugs available for treating herpetic keratitis, and seems especially useful in 'difficult' cases."
01/01/1979 - "[Treatment of herpetic keratitis with trifluorothymidine]."
04/01/2004 - "The objective of the study was to analyze the efficiency of trifluridine in the treatment of herpes infection of the cornea. "
04/01/1982 - "However, bromovinyldeoxyuridine and trifluridine were equally effective if the treatment was started seven days after infection. "
07/01/1992 - "Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections."
04/01/1968 - "Studies of adenovirus type 3 infection treated with methisazone and trifluorothymidine."
01/01/1991 - "Therapy with 1% trifluorothymidine (F3TdR) alone or in combination with immunosuppressive agents was initiated 7 days post-infection, at a time when epithelial disease had reached its peak and corneal thickness had begun to increase. "
10/01/1985 - "Association of trifluorothymidine and débridement in herpetic dendritic keratitis."
10/01/1978 - "In a randomized double-blind study trifluorothymidine was tested for its ability to prevent dendritic keratitis at a dose of 5 drops daily in patients with steroid-treated herpetic keratouveitis. "
01/01/1985 - "23 patients with proven herpetic dendritic keratitis have been treated with combined blunt spatula debridement and trifluorothymidine. "
01/01/1985 - "Combined treatment of herpetic dendritic keratitis with blunt spatula debridement and trifluorothymidine."
05/01/1985 - "Our results suggest that débridement alone is suboptimal therapy for herpes simplex dendritic keratitis and that débridement combined with trifluridine appears to offer no advantage over trifluridine alone."
|5.||Colorectal Neoplasms (Colorectal Cancer)
05/14/2015 - "Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. "
07/01/2015 - "In May 2014, tablets containing both trifluridine and tipiracil hydrochloride (Lonsurf® tablets) were launched in Japan ahead of other countries, for the treatment of advanced/relapsed unresectable colorectal cancer. "
05/01/2015 - "TAS-102 is a novel oral nucleoside antitumor agent that consists of trifluridine (FTD) and tipiracil hydrochloride (TPI) at a molecular ratio of 1:0.5, and was approved in Japan in March 2014 for the treatment of patients with unresectable advanced or recurrent colorectal cancer that is refractory to standard therapies. "
01/29/2007 - "Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells."
09/01/2015 - "TAS-102, which is effective for refractory metastatic colorectal cancer, is a combination drug of anticancer trifluridine (FTD; which is derived from pyrimidine nucleoside) and FTD-metabolizing enzyme inhibitor tipiracil hydrochloride (TPI) at a molecular ratio of 1:0.5. "
|8.||Antiviral Agents (Antivirals)
|9.||Interferon-alpha (Interferon Alfa)
|10.||Ophthalmic Solutions (Eye Drops)
|3.||Transplantation (Transplant Recipients)